1. Home
  2. IDN vs SCYX Comparison

IDN vs SCYX Comparison

Compare IDN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDN
  • SCYX
  • Stock Information
  • Founded
  • IDN 1994
  • SCYX 1999
  • Country
  • IDN United States
  • SCYX United States
  • Employees
  • IDN 47
  • SCYX N/A
  • Industry
  • IDN Computer Software: Prepackaged Software
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IDN Technology
  • SCYX Health Care
  • Exchange
  • IDN Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • IDN 46.8M
  • SCYX 40.9M
  • IPO Year
  • IDN 1999
  • SCYX 2014
  • Fundamental
  • Price
  • IDN $2.43
  • SCYX $0.90
  • Analyst Decision
  • IDN Buy
  • SCYX
  • Analyst Count
  • IDN 2
  • SCYX 0
  • Target Price
  • IDN $3.00
  • SCYX N/A
  • AVG Volume (30 Days)
  • IDN 103.2K
  • SCYX 94.5K
  • Earning Date
  • IDN 05-12-2025
  • SCYX 05-07-2025
  • Dividend Yield
  • IDN N/A
  • SCYX N/A
  • EPS Growth
  • IDN N/A
  • SCYX N/A
  • EPS
  • IDN N/A
  • SCYX N/A
  • Revenue
  • IDN $19,997,000.00
  • SCYX $3,746,000.00
  • Revenue This Year
  • IDN $7.60
  • SCYX $460.12
  • Revenue Next Year
  • IDN $10.02
  • SCYX $253.87
  • P/E Ratio
  • IDN N/A
  • SCYX N/A
  • Revenue Growth
  • IDN 5.77
  • SCYX N/A
  • 52 Week Low
  • IDN $1.92
  • SCYX $0.73
  • 52 Week High
  • IDN $4.46
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • IDN 46.11
  • SCYX 45.97
  • Support Level
  • IDN $2.28
  • SCYX $0.89
  • Resistance Level
  • IDN $2.54
  • SCYX $0.99
  • Average True Range (ATR)
  • IDN 0.23
  • SCYX 0.08
  • MACD
  • IDN -0.02
  • SCYX 0.01
  • Stochastic Oscillator
  • IDN 24.07
  • SCYX 64.71

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: